Balyasny Asset Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Balyasny Asset Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-29,032	Closed	-$151K	–	2106
2018 Q2	$151K	Sell	29,032 -2,692	-8%	-$16.4K	﹤0.01%	1675
2018 Q1	$174K	Buy	31,724 +21,272	+204%	+$150K	﹤0.01%	1780
2017 Q4	$85K	Sell	10,452 -10,200	-49%	-$97.4K	﹤0.01%	1987
2017 Q3	$216K	Buy	+20,652	New	+$229K	﹤0.01%	1679
2017 Q2	–	Sell	-26,628	Closed	-$223K	–	1813
2017 Q1	$223K	Buy	+26,628	New	+$188K	﹤0.01%	1464
2015 Q3	–	Sell	-14,820	Closed	-$45K	–	1430
2015 Q2	$45K	Buy	+14,820	New	+$41.7K	﹤0.01%	1107

Other funds holding ENZ

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balyasny Asset Management's ENZ Position: Q3 2018 in Review

Balyasny Asset Management sold out of Enzo Biochem, Inc. (ENZ) in Q3 2018, closing a stake of 29,032 shares — an estimated $151K sold.

Balyasny Asset Management first reported a position in ENZ in Q2 2015 and held it in 6 quarters. The position peaked at $223K in Q1 2017. 101 funds tracked by Wall St. Rank hold ENZ as of Q3 2018.

Balyasny Asset Management reported no remaining Enzo Biochem, Inc. position as of Q3 2018 after selling out during the quarter.
Balyasny Asset Management sold 29,032 Enzo Biochem, Inc. shares in Q3 2018, an estimated $151K.
Balyasny Asset Management first reported a position in Enzo Biochem, Inc. in Q2 2015 and held it in 6 quarters.
Balyasny Asset Management's Enzo Biochem, Inc. position peaked at $223K in Q1 2017.
101 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.